REPL · Replimune Group, Inc.
$13.15
+0.08 (+0.61%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.16B
Shares
94.22M
Volume · Oct 5
2.28M
Avg daily vol (3M)
4.24M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.07
Open$13.69
Day$12.80–13.83
52W close$1.70–15.98
Avg vol 30d2.2M
Short int22.8M · 24.2% float · 11.1d
Short vol43%
Last earningsAug 14, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Feb 27, 2028
Est · unconfirmed
· in 73 wks
filed Aug 14, 2026
call held May 22, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$297.01M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$111.21M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.8%
Year over year · more shares
Price change (1Y)
+181.1%
Trailing year
Short interest
24.2%
Latest settlement · 11.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+46%
above
Price vs 50-day avg
−1%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
80%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+175%
trailing
YTD return
+34%
this year
Relative strength
+162%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Flat
1 of 204 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$1.0M over 90 days · 100% sells
Short interest
Falling
24.15% of float · ▼ -3.3% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
204 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
−10%
Y/Y
Free cash flow
$-282.6M
Balance sheet
$117.9M
net cash
Quant / Vol
risk profile
Volatility
211%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+46%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
80%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $13 › 200d $9 — 50d above 200d
Institutional flow
Flat
1 of 204 funds reported for Sep 30 · net 0 sh shares
Insider flow
Distributing
Net -$1.0M over 90 days · 100% sells
Short interest
Falling
24.15% of float · ▼ -3.3% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
204 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $13 · 80%
Range high $16
vs 200-day avg +46%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REPL
this stock
Replimune Group, Inc.
|
$1.16B | +34.5% | — | — | 24.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REPL | +5.7% | -14.5% | +174.6% | -1.3% | +34.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +6.0% | -14.1% | +162.4% | -2.2% | +21.6% |